BlueDot is pleased to welcome Dr. Andrea Thomas, Jannine Krish and Les Lengyel to the leadership team.
BlueDot’s newly appointed leadership team comes at a time when the market need for infectious disease intelligence is rising, so governments and private sector organizations can make critical decisions with more agility and better insights.
TORONTO (PRWEB)
October 25, 2022
BlueDot Inc., the leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious diseases, announced the expansion of its executive team as it enters its next phase of growth. As part of the company’s continued work in building private and public sectors’ resiliency to outbreaks, BlueDot announced the hires of Les Lengyel, Vice President of Sales and Jannine Krish, Vice President of Marketing, in addition to the promotion of Dr. Andrea Thomas to Director of Epidemiology.
Les Lengyel is a tenured leader in the AI SaaS, Life Sciences and MedTech sectors, and brings to BlueDot a keen ability to drive significant growth having achieved revenue increases year over year and tripled purchase order growth in previous roles. With over a decade in Philips Healthcare and Roche respectively alone, he brings a critical understanding of how to drive successful key initiatives and company growth.
Jannine Krish is an experienced marketing leader with 15 years of experience in building and scaling iconic Canadian startups and enterprise brands on a global stage. Through a combination of storytelling and performance marketing, she’s led marketing strategies that build industry leadership, consumer trust and business results. Jannine has held senior marketing roles at Flybits, Union Pearson Express and Porter Airlines.
Dr. Andrea Thomas has been a predominant figure in driving excellence in epidemiology at BlueDot over the past five years. She led the data science team in introducing innovative approaches to data science throughout the pandemic and maintains academic excellence with frequent publications, including the world’s first publication on COVID-19 and a publication estimating potential global exportation of monkeypox. Dr. Thomas holds a Doctor of Veterinary Medicine degree, along with a Masters and PhD in Epidemiology.
“Our company went through a rapid phase of growth during the height of the COVID 19 pandemic,” said Dr. Kamran Khan, Founder and CEO, BlueDot. “Now as we prepare for this next phase of growth, I’m excited about deepening our pool of talented leaders to expand our global reach and impact.”
BlueDot’s newly appointed leadership team comes at a time when the market need for infectious disease intelligence is rising, so governments and private sector organizations can make critical decisions with more agility and better insights.
About BlueDot
BlueDot’s intelligence platform empowers public and private sector organizations to rapidly identify, understand, and effectively respond to global biothreats. Combining human and artificial intelligence to track hundreds of infectious diseases and syndromes worldwide, it applies academic data science expertise to anticipate global spread and impact. BlueDot ensures clients know first when disease events emerge, are prepared to respond, can focus on what matters, and can act swiftly and confidently when needed. Founded in 2013 and used by the City of Chicago, Taiwan CDC, Air Canada and more, BlueDot helps clients make critical decisions with clarity and confidence. Learn more at http://www.bluedot.global
Share article on social media or email: